Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | TGM2 | P21980 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.35 |
| ▸ | SCD | O00767 | 1/20 | 0.35 |
| ▸ | GLS | O94925 | 3/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25333230 | 0.83 | DPP4 (0.47) | DPP4NOTUMCA5ATGM2ALDH1A1 | |
| SCHEMBL20615682 | 0.82 | DPP4 (0.40) | DPP4NOTUMCA5ATGM2ALDH1A1 | |
| SCHEMBL30322972 | 0.80 | DPP4 (0.45) | DPP4NOTUMGLSHDAC9 | |
| SCHEMBL30322942 | 0.78 | ALDH1A1 (0.59) | ALDH1A1LMNA | |
| SCHEMBL27144814 | 0.77 | SRC (0.50) | GGPS1NR1H4 | |
| SCHEMBL15589751 | 0.76 | DPP4 (0.50) | DPP4NOTUMCA5ATGM2ALDH1A1 | |
| SCHEMBL4134269 | 0.76 | DPP4 (0.43) | DPP4CA5ATGM2ALDH1A1LMNA | |
| SCHEMBL6072289 | 0.76 | ALDH1A1 (0.45) | DPP4CA5ATGM2ALDH1A1LMNA | |
| SCHEMBL31124067 | 0.75 | DPP4 (0.49) | DPP4NOTUMCA5ATGM2ALDH1A1 | |
| SCHEMBL17630704 | 0.74 | DPP4 (0.48) | DPP4CA5ATGM2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376085-A1 | BENZIMIDAZOLES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2024-11-14 | — | — | US | disclosed |
| EP-4408530-A1 | BENZIMIDAZOLES AS MODULATORS OF IL-17 | Janssen Pharmaceutica NV (BE) | 2024-08-07 | — | — | EP | disclosed |
| WO-2023049888-A1 | BENZIMIDAZOLES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-30 | — | — | WO | disclosed |
| EP-1713778-B1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376085-A1 | BENZIMIDAZOLES AS MODULATORS OF IL-17 | IL17A, IL23R, IL4I1 | DPP4 2900/4885NOTUM 4415/4885CA5A 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.